NCT05733689 2026-03-10
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
University of California, Irvine
Phase 1 Recruiting
Clinical Trials
17 trialsNCT04585477 2026-02-10
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford University
Phase 2 Recruiting
NCT06008691 2025-12-29
FIL_MAB
Fondazione Italiana Linfomi - ETS
Recruiting
NCT07260435 2025-12-03
Apa/Enza-short
Erasmus Medical Center
Phase 3 Recruiting
NCT07129772 2025-09-04
Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma
The University of Hong Kong
Phase 2 Not yet recruiting
NCT06030622 2024-04-19
C3
State University of New York - Downstate Medical Center
Phase 1/2 Recruiting
NCT06107478 2023-10-30
MASSAYA
Centre Leon Berard
Unknown
NCT03921996 2023-03-09
Extended Pelvic Lymph Node Dissection vs. no Pelvic Lymph Node Dissection at Radical Prostatectomy for intermediate-and High-risk Prostate Cancer
Swiss Cancer Institute
Phase 3 Terminated
NCT02978222 2022-12-15
Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer
Marker Therapeutics, Inc.
Phase 2 Terminated
NCT04784026 2021-03-05
Dual Task Gait Performance in Pediatric Oncology Patients
Afyonkarahisar Health Sciences University
Unknown
NCT00260832 2019-09-11
Trial of Decitabine in Patients With Acute Myeloid Leukemia
Eisai Inc.
Phase 3 Completed
NCT03347045 2017-11-20
TPC-RCT
Alberta Health Services, Calgary
Phase NA Unknown
NCT01015443 2016-10-26
INSPIRE
Merck KGaA, Darmstadt, Germany
Phase 3 Terminated
NCT00157209 2015-11-18
Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)
Merck KGaA, Darmstadt, Germany
Phase 2 Completed
NCT00960115 2015-10-21
Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed
NCT00157196 2015-08-18
Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease
Merck KGaA, Darmstadt, Germany
Phase 2 Completed
NCT00352859 2014-12-30
Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib
Bayer
Phase 4 Terminated